Daily stock market analysis, trade alerts, and trading education from Ross Givens and the Traders Agency team.
Lightspeed trading review verdict: a powerful direct market access broker built for active day traders, not beginners. See fees, minimums, and platform too
Smart money biotech stocks are taking the lead as capital rotates out of semis. IMVT and TGTX show tight setups with institutional money flow backing the m
Barchart review verdict: strong pick for futures, commodities, and options flow. See who benefits most from free access vs Premier subscription.
The next GameStop meme stock may already be forming. Jack in the Box has tiny float, high short interest, and WallStreetBets attention — the exact GME setu
Market Chameleon review: is it worth it for options traders? We break down implied volatility tools, earnings analytics, and pricing so you can decide.
Oil tanker stocks are quietly minting cash as VLCC day rates hit $470K/day — triple last month's levels. Here's why falling oil prices mean rising tanker p
Vera Therapeutics stock faces an FDA decision July 7. Phase 3 crushed expectations with 46% kidney protein reduction. Wall Street targets $83.50 on this $3
Government quantum computing investment just hit $2B across 9 private firms. These 2 picks-and-shovels stocks sit in the direct path of that funding.
Option Alpha review: no-code bot builder, unlimited backtesting, and automated options trading for retail traders. See who it's built for and what it deliv
The 2026 market rotation is here — NASDAQ down 3% while biotech and quantum computing surge. IOVA and LAES are breaking out as capital flees semiconductors
Koyfin review: a Bloomberg alternative built for retail traders. See who it's best for, what the data covers, and whether free or pro fits your needs.
50,000+ traders get our daily brief before the market opens.
You're subscribed!
Check your inbox.
Free. No spam. Unsubscribe anytime.